Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Sees Large Increase in Short Interest

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 693,000 shares, an increase of 310.3% from the December 15th total of 168,900 shares. Based on an average trading volume of 3,270,000 shares, the days-to-cover ratio is presently 0.2 days.

Insider Transactions at Quoin Pharmaceuticals

In other Quoin Pharmaceuticals news, CFO Gordon Dunn acquired 122,221 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $0.45 per share, with a total value of $54,999.45. Following the completion of the acquisition, the chief financial officer now directly owns 151,077 shares of the company’s stock, valued at approximately $67,984.65. The trade was a 423.55 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Denise P. Carter bought 555,556 shares of Quoin Pharmaceuticals stock in a transaction on Monday, December 23rd. The stock was acquired at an average cost of $0.45 per share, with a total value of $250,000.20. Following the acquisition, the chief operating officer now owns 602,648 shares of the company’s stock, valued at $271,191.60. This trade represents a 1,179.72 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 777,777 shares of company stock worth $350,000 over the last ninety days. 3.70% of the stock is currently owned by company insiders.

Quoin Pharmaceuticals Trading Down 8.0 %

Shares of QNRX stock traded down $0.05 during mid-day trading on Monday, reaching $0.57. The stock had a trading volume of 225,882 shares, compared to its average volume of 562,820. The company has a market cap of $2.89 million, a P/E ratio of -0.14 and a beta of 1.75. Quoin Pharmaceuticals has a 12-month low of $0.43 and a 12-month high of $6.18. The business has a 50-day simple moving average of $0.64 and a 200 day simple moving average of $0.63.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.